IBOV 172,236.05 ▲ 2.22% IPC MEX 71,866.30 ▲ 0.66% MERVAL 2,848,945 — — USD/BRL5.51▲ 0.05% USD/MXN18.45▼ 0.45% USD/CLP966.96▼ 0.99% USD/COP3,267▲ 4.70% USD/PEN3.41▼ 1.07% USD/ARS1,545▼ 0.02% USD/UYU40.45▲ 0.35% USD/PYG6,450▲ 1.45% USD/BOB11.74▼ 0.59% USD/DOP60.46▲ 2.41% USD/CRC446.56▼ 0.38% USD/GTQ7.64▼ 0.05% USD/HNL26.89▲ 0.02% USD/NIO36.62▲ 2.53% USD/VES897.02▲ 0.07% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.79▲ 2.42% USD/TTD6.72▼ 0.03% EUR/BRL6.19▲ 0.99% BRENT 90.82 ▼ 1.89% WTI 85.12 ▼ 1.99% IRON ORE 161.91 — — COPPER 6.32 ▼ 0.21% GOLD 4,124 ▲ 0.24% SILVER 52.79 ▲ 0.42% SOY 1,196 ▲ 1.12% CORN 441.50 ▲ 0.51% WHEAT 591.25 ▲ 0.55% COFFEE 266.70 ▼ 4.75% SUGAR 18.21 ▼ 0.16% ORANGE JUICE 143.50 ▲ 7.85% COTTON 78.65 ▼ 0.58% COCOA 5,113 ▼ 0.81% BEEF 216.33 ▲ 1.06% CATTLE 324.80 ▲ 0.77% LITHIUM 61.35 ▲ 0.72% PETR4 45.19 ▼ 0.24% VALE3 66.11 ▲ 3.23% ITUB4 41.72 ▲ 2.94% BBDC4 14.68 ▲ 3.38% ABEV3 15.61 ▲ 0.84% BBAS3 17.02 ▼ 0.64% B3SA3 14.85 ▲ 3.20% WEGE3 50.74 ▲ 5.29% PRIO3 59.39 ▼ 1.80% SUZB3 54.20 ▲ 1.50% RENT3 30.83 ▲ 1.78% AZZA3 15.12 ▲ 2.44% CSAN3 2.77 — 0.00% RAIZ4 24.40 ▼ 12.86% PCAR3 2.43 ▲ 1.25% GMAT3 3.83 ▲ 0.79% PSSA3 45.65 ▲ 2.93% CVCB3 0.87 ▲ 3.57% POSI3 3.03 ▼ 1.94% SLCE3 17.30 ▲ 4.15% NATU3 5.71 ▲ 10.44% BRKM5 3.02 ▼ 5.63% RANI3 8.76 ▲ 3.44% CSNA3 4.49 ▲ 1.81% IBOV 172,236.05 ▲ 2.22% IPC MEX 71,866.30 ▲ 0.66% MERVAL 2,848,945 — — USD/BRL 5.51 ▲ 0.05% USD/MXN 18.45 ▼ 0.42% USD/CLP 966.96 ▼ 0.99% USD/COP 3,267 ▲ 4.70% USD/PEN 3.41 ▼ 1.07% USD/ARS 1,545 ▼ 0.02% USD/UYU 40.45 ▲ 0.35% USD/PYG 6,450 ▲ 1.45% USD/BOB 11.74 ▼ 0.59% USD/DOP 60.46 ▲ 2.41% USD/CRC 446.56 ▼ 0.38% USD/GTQ 7.64 ▼ 0.05% USD/HNL 26.89 ▲ 0.02% USD/NIO 36.62 ▲ 2.53% USD/VES 897.02 ▲ 0.07% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.79 ▲ 2.42% USD/TTD 6.72 ▲ 2.10% EUR/BRL 6.19 ▲ 0.99% BRENT 90.82 ▼ 1.89% WTI 85.12 ▼ 1.99% IRON ORE 161.91 — — COPPER 6.32 ▼ 0.21% GOLD 4,124 ▲ 0.24% SILVER 52.79 ▲ 0.42% SOY 1,196 ▲ 1.12% CORN 441.50 ▲ 0.51% WHEAT 591.25 ▲ 0.55% COFFEE 266.70 ▼ 4.75% SUGAR 18.21 ▼ 0.16% ORANGE JUICE 143.50 ▲ 7.85% COTTON 78.65 ▼ 0.58% COCOA 5,113 ▼ 0.81% BEEF 216.33 ▲ 1.06% CATTLE 324.80 ▲ 0.77% LITHIUM 61.35 ▲ 0.72% PETR4 45.19 ▼ 0.24% VALE3 66.11 ▲ 3.23% ITUB4 41.72 ▲ 2.94% BBDC4 14.68 ▲ 3.38% ABEV3 15.61 ▲ 0.84% BBAS3 17.02 ▼ 0.64% B3SA3 14.85 ▲ 3.20% WEGE3 50.74 ▲ 5.29% PRIO3 59.39 ▼ 1.80% SUZB3 54.20 ▲ 1.50% RENT3 30.83 ▲ 1.78% AZZA3 15.12 ▲ 2.44% CSAN3 2.77 — 0.00% RAIZ4 24.40 ▼ 12.86% PCAR3 2.43 ▲ 1.25% GMAT3 3.83 ▲ 0.79% PSSA3 45.65 ▲ 2.93% CVCB3 0.87 ▲ 3.57% POSI3 3.03 ▼ 1.94% SLCE3 17.30 ▲ 4.15% NATU3 5.71 ▲ 10.44% BRKM5 3.02 ▼ 5.63% RANI3 8.76 ▲ 3.44% CSNA3 4.49 ▲ 1.81%
since 2009
Tuesday, November 10, 2026

Covid-19 Brazil

Brazilian Approval of Sputnik V Vaccine Delayed by Missing Data

By · · 2 min read

RIO DE JANEIRO, BRAZIL – Brazil’s health regulator is seeking further data on Russia’s Sputnik V coronavirus vaccine before considering its approval for emergency use.

Documents supporting drugmaker União Química’s application for emergency use of the vaccine have been returned to the company because they did not meet its minimum criteria, the watchdog said on Saturday, January 16th.

Brazil’s health regulator is seeking further data on Russia’s Sputnik V coronavirus vaccine before considering its approval for emergency use.
Brazil’s health regulator is seeking further data on Russia’s Sputnik V coronavirus vaccine before considering its approval for emergency use. PHOTO: Bottles of Russia's "Sputnik-V" COVID-19 vaccine are seen before inoculation at a clinic in Tver, Russia, October 12, 2020. REUTERS/Tatyana Makeyeva/File Photo
RT
Ask Rio Times
This story and the bigger picture.
Open the full Ask Rio Times →

In a statement on the Health Ministry’s website, regulator ANVISA said the request failed to provide adequate assurances on Phase III clinical trials and issues related to the manufacture of the vaccine.

União Quimíca is seeking approval for the use of 10 million doses of Sputnik V in Brazil in the first quarter of this year.

Russia’s RDIF sovereign wealth fund, which is promoting Sputnik globally, on Sunday said that ANVISA had requested additional information that would be provided shortly.

Its statement said that such requests from regulators were standard procedure and do not mean the registration bid has been rejected. It also said that legislation going through the Brazilian Senate, if approved, would allow use of vaccines approved by other countries.

Moscow has approved Sputnik-V for Russian domestic use, though clinical trials there have not yet been completed. RDIF said that Sputnik-V had already been registered in Serbia, Belarus, Argentina, Bolivia, Algeria, Venezuela, Paraguay and by the Palestinian authorities. Registrations in two more countries are expected next week, it added.

ANVISA officials had previously said that the Sputnik-V vaccine would have to be submitted to Phase III clinical trials in Brazil before its use could be authorised.

ANVISA said on Saturday that any applicant requesting emergency use authorisation must show that the vaccine would deliver long-term safety and effectiveness.

The regulator is expected to make a decision on Sunday about authorising emergency use of vaccines developed by China’s Sinovac and Britain’s AstraZeneca.

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.